Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,171 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combination of clofarabine, etoposide, and cyclophosphamide in adult relapsed/refractory acute lymphoblastic leukemia: a phase 1/2 dose-escalation study by the Japan Adult Leukemia Study Group.
Saito T, Hatta Y, Hayakawa F, Takahashi T, Hagihara M, Iida H, Minauchi K, Yamazaki E, Sugiura I, Murayama T, Sakura T, Mori N, Imai K, Yahagi Y, Atsuta Y, Saito AM, Hirakawa A, Kiyoi H, Matsumura I, Miyazaki Y; Japan Adult Leukemia Study Group. Saito T, et al. Among authors: murayama t. Int J Hematol. 2021 Mar;113(3):395-403. doi: 10.1007/s12185-020-03032-3. Epub 2020 Nov 23. Int J Hematol. 2021. PMID: 33230647 Clinical Trial.
Optimal treatment for Philadelphia-negative acute lymphoblastic leukemia in first remission in the era of high-intensity chemotherapy.
Kako S, Hayakawa F, Imai K, Tanaka J, Mizuta S, Nishiwaki S, Kanamori H, Mukae J, Ozawa Y, Kondo T, Fukuda T, Ichinohe T, Ota S, Tanaka Y, Murayama T, Kurahashi S, Sakura T, Usui N, Ohtake S, Kiyoi H, Matsumura I, Miyazaki Y, Atsuta Y. Kako S, et al. Among authors: murayama t. Int J Hematol. 2021 Nov;114(5):608-619. doi: 10.1007/s12185-021-03198-4. Epub 2021 Jul 30. Int J Hematol. 2021. PMID: 34328634
High-dose methotrexate therapy significantly improved survival of adult acute lymphoblastic leukemia: a phase III study by JALSG.
Sakura T, Hayakawa F, Sugiura I, Murayama T, Imai K, Usui N, Fujisawa S, Yamauchi T, Yujiri T, Kakihana K, Ito Y, Kanamori H, Ueda Y, Miyata Y, Kurokawa M, Asou N, Ohnishi K, Ohtake S, Kobayashi Y, Matsuo K, Kiyoi H, Miyazaki Y, Naoe T. Sakura T, et al. Among authors: murayama t. Leukemia. 2018 Mar;32(3):626-632. doi: 10.1038/leu.2017.283. Epub 2017 Sep 15. Leukemia. 2018. PMID: 28914260 Clinical Trial.
Myeloablative intravenous busulfan-containing regimens for allo-HSCT in AML or MDS patients over 54 years old: combined results of three phase II studies.
Uchida N, Matsumoto K, Sakura T, Hidaka M, Miyamoto T, Eto T, Maeda Y, Murayama T, Fujishima N, Yoshimoto G, Morita K, Kishimoto J, Teshima T, Taniguchi S, Yamashita T, Mori SI, Akashi K, Harada M; Japan Study Group for Cell Therapy, Transplantation (JSCT). Uchida N, et al. Among authors: murayama t. Int J Hematol. 2020 Oct;112(4):510-523. doi: 10.1007/s12185-020-02941-7. Epub 2020 Jul 12. Int J Hematol. 2020. PMID: 32656637
Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations.
Yasuda T, Sanada M, Kawazu M, Kojima S, Tsuzuki S, Ueno H, Iwamoto E, Iijima-Yamashita Y, Yamada T, Kanamori T, Nishimura R, Kuwatsuka Y, Takada S, Tanaka M, Ota S, Dobashi N, Yamazaki E, Hirose A, Murayama T, Sumi M, Sato S, Tange N, Nakamura Y, Katsuoka Y, Sakaida E, Kawamata T, Iida H, Shiraishi Y, Nannya Y, Ogawa S, Taniwaki M, Asou N, Hatta Y, Kiyoi H, Matsumura I, Horibe K, Mano H, Naoe T, Miyazaki Y, Hayakawa F. Yasuda T, et al. Among authors: murayama t. Blood. 2022 Mar 24;139(12):1850-1862. doi: 10.1182/blood.2021011921. Blood. 2022. PMID: 34695176 Free article.
Phase II study of tacrolimus and methotrexate for prophylaxis of acute graft-versus-host disease after HLA-A, B, and DRB1 genotypically mismatched unrelated bone marrow transplantation among Japanese patients.
Nishida T, Murayama T, Hirai H, Okamoto S, Sao H, Hara M, Kanamori H, Atsuta Y, Matsuo K, Morishima Y, Kodera Y. Nishida T, et al. Among authors: murayama t. Int J Hematol. 2009 Jan;89(1):98-105. doi: 10.1007/s12185-008-0219-8. Epub 2008 Dec 4. Int J Hematol. 2009. PMID: 19052693 Clinical Trial.
Efficacy and safety of obinutuzumab in patients with previously untreated follicular lymphoma: a subgroup analysis of patients enrolled in Japan in the randomized phase III GALLIUM trial.
Ohmachi K, Tobinai K, Kinoshita T, Ishikawa T, Hatake K, Ichikawa S, Ohmine K, Kamitsuji Y, Choi I, Chou T, Tsukasaki K, Kumagai K, Taniwaki M, Uchida T, Kikukawa Y, Kubo K, Mihara K, Tsukamoto N, Izutsu K, Yoshida I, Ishida F, Usui N, Iida S, Murayama T, Ueda E, Kuriki H, Ando K. Ohmachi K, et al. Among authors: murayama t. Int J Hematol. 2018 Nov;108(5):499-509. doi: 10.1007/s12185-018-2497-0. Epub 2018 Jul 19. Int J Hematol. 2018. PMID: 30027429 Clinical Trial.
Efficacy of upfront high-dose chemotherapy plus rituximab followed by autologous peripheral blood stem cell transplantation for untreated high-intermediate-, and high-risk diffuse large B-cell lymphoma: a multicenter prospective phase II study (JSCT-NHL04).
Murayama T, Fukuda T, Okumura H, Sunami K, Sawazaki A, Maeda Y, Tsurumi H, Uike N, Hidaka T, Takatsuka Y, Eto T, Tsuda H, Fujisaki T, Miyamoto T, Tsuneyoshi N, Iyama S, Nagafuji K, Harada M. Murayama T, et al. Int J Hematol. 2016 Jun;103(6):676-85. doi: 10.1007/s12185-016-1976-4. Epub 2016 Mar 21. Int J Hematol. 2016. PMID: 27084252 Clinical Trial.
Multicenter phase 1/2 study of forodesine in patients with relapsed peripheral T cell lymphoma.
Maruyama D, Tsukasaki K, Uchida T, Maeda Y, Shibayama H, Nagai H, Kurosawa M, Suehiro Y, Hatake K, Ando K, Yoshida I, Hidaka M, Murayama T, Okitsu Y, Tsukamoto N, Taniwaki M, Suzumiya J, Tamura K, Yamauchi T, Ueda R, Tobinai K. Maruyama D, et al. Among authors: murayama t. Ann Hematol. 2019 Jan;98(1):131-142. doi: 10.1007/s00277-018-3418-2. Epub 2018 Jul 5. Ann Hematol. 2019. PMID: 29974231 Free PMC article. Clinical Trial.
Durable response but prolonged cytopenia after cladribine treatment in relapsed patients with indolent non-Hodgkin's lymphomas: results of a Japanese phase II study.
Ogura M, Morishima Y, Kobayashi Y, Uike N, Sugai S, Chou T, Kasai M, Miura I, Murayama T, Matsuno Y, Nakamura S, Mori S, Ohashi Y, Tobinai K; Cladribine Study Group. Ogura M, et al. Among authors: murayama t. Int J Hematol. 2004 Oct;80(3):267-77. doi: 10.1532/ijh97.04077. Int J Hematol. 2004. PMID: 15540903 Clinical Trial.
1,171 results